<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326338</url>
  </required_header>
  <id_info>
    <org_study_id>RM02-3019</org_study_id>
    <nct_id>NCT01326338</nct_id>
  </id_info>
  <brief_title>Nitazoxanide for the Treatment of Prolonged Diarrhea in Children</brief_title>
  <official_title>Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Prolonged Diarrhea in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the efficacy of nitazoxanide suspension compared
      to placebo in treating prolonged diarrhea in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from first dose to resolution of symptoms</measure>
    <time_frame>Up to 17 days</time_frame>
    <description>Resolution of symptoms defined as resolution of all gastrointestinal symptoms associated with prolonged diarrhea at enrollment including abdominal pain or tenderness, distention, etc. with the patient not requiring anti-motility or other palliative treatment. Symptom resolution must be maintained for at least 72 hours to be considered valid.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days</description>
    <arm_group_label>Nitazoxanide Suspension</arm_group_label>
    <arm_group_label>Placebo Suspension</arm_group_label>
    <other_name>Alinia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diarrhea â‰¥3 days but &lt;30 days duration.

          -  No visible blood in stool.

        Exclusion Criteria:

          -  Use of any antibacterial, antiparasitic or antiviral drugs within 5 days of
             enrollment.

          -  Females who are pregnant, suspected of being pregnant or breastfeeding.

          -  Serious systemic disorders incompatible with the study.

          -  History of hypersensitivity to nitazoxanide.

          -  Patients in whom the possibility of receiving placebo and not being able to receive
             immediately an effective treatment will be incompatible with the severity of the
             patient's illness according to the investigator's judgment.

          -  Patients known to have or suspected of having AIDS or other immune deficiencies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital of Cajamarca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Hospital of Cajamarca</name>
      <address>
        <city>Cajamarca</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Celine Rossignol, MS</name_title>
    <organization>Romark Laboratories, L.C.</organization>
  </responsible_party>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

